Trials / Completed
CompletedNCT03256838
Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- Panion & BF Biotech Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the long-term safety and effectiveness of Nephoxil® for the treatment of hyperphosphatemia in patients with ESRD undergoing dialysis.
Detailed description
This study is an open-label, prospective, long term, Phase IV study to assess the safety and efficacy of Nephoxil® in subjects with ESRD on dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ferric Citrate | Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels. |
Timeline
- Start date
- 2017-04-12
- Primary completion
- 2018-12-31
- Completion
- 2019-05-31
- First posted
- 2017-08-22
- Last updated
- 2020-01-13
Locations
9 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03256838. Inclusion in this directory is not an endorsement.